

REGENERON PHARMACEUTICALS INC  
 Form 4  
 February 26, 2014

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**GOLDBERG MURRAY A**

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN, NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**REGENERON PHARMACEUTICALS INC [REGN]**

3. Date of Earliest Transaction (Month/Day/Year)  
 02/24/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 \_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
 SVP Administration & Asst Sec

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | (A) or (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|------------|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount     | Price   |  |   |
| Common Stock                    | 02/24/2014                           |  | M <sup>(1)</sup>               |   | 6,334      | \$ 90.07  | D  |   |
| Common Stock                    | 02/24/2014                           |  | F <sup>(1)</sup>               |   | 1,664      | \$ 342.63   | D  |   |
| Common Stock                    | 02/24/2014                           |  | F <sup>(1)</sup>               |   | 2,407      | \$ 342.63   | D  |   |
| Common Stock                    | 02/24/2014                           |  | M <sup>(1)</sup>               |   | 20,000     | \$ 52.03  | D  |   |
|                                 | 02/24/2014                           |  | F <sup>(1)</sup>               |   | 3,036      |   | D  |   |

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

|              |            |              |       |   |  |                   |        |   |                |
|--------------|------------|--------------|-------|---|--|-------------------|--------|---|----------------|
| Common Stock |            |              |       |   |  | \$ 342.63         |        |   |                |
| Common Stock | 02/24/2014 | <u>F</u> (1) | 8,747 | D |  | \$ 342.63         | 73,582 | D |                |
| Common Stock | 02/24/2014 | <u>M</u> (1) | 3,893 | A |  | \$ 90.07          | 77,475 | D |                |
| Common Stock | 02/24/2014 | <u>F</u> (1) | 1,023 | D |  | \$ 342.63         | 76,452 | D |                |
| Common Stock | 02/24/2014 | <u>F</u> (1) | 1,479 | D |  | \$ 342.63         | 74,973 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 275   | D |  | \$ 336.89<br>(2)  | 74,698 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 1,962 | D |  | \$ 337.4<br>(3)   | 72,736 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 3,934 | D |  | \$ 338.37<br>(4)  | 68,802 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 1,300 | D |  | \$ 339.2<br>(5)   | 67,502 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 1,200 | D |  | \$ 340.43<br>(6)  | 66,302 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 2,100 | D |  | \$ 341.46<br>(7)  | 64,202 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 500   | D |  | \$ 342.19<br>(8)  | 63,702 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 200   | D |  | \$ 344.47<br>(9)  | 63,502 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 100   | D |  | \$ 345.02         | 63,402 | D |                |
| Common Stock | 02/25/2014 | <u>S</u> (1) | 300   | D |  | \$ 346.73<br>(10) | 63,102 | D |                |
| Common Stock |            |              |       |   |  |                   | 5,650  | I | By 401(k) Plan |
| Common Stock |            |              |       |   |  |                   | 750    | I | by Spouse      |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | 8. Amount or Number of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|---|
| Non-Qualified Stock Option (right to buy)  | \$ 52.03   | 02/24/2014                           |  | M <sup>(1)</sup>               | 20,000  | <sup>(11)</sup> 12/16/2021                               | Common Stock  | 20  |
| Non-Qualified Stock Option (right to buy)  | \$ 90.07   | 02/24/2014                           |  | M <sup>(1)</sup>               | 6,334   | 01/31/2012 12/18/2016                                    | Common Stock  | 6   |
| Non-Qualified Stock Option (right to buy)  | \$ 90.07   | 02/24/2014                           |  | M <sup>(1)</sup>               | 3,893   | 01/31/2012 12/17/2017                                    | Common Stock  | 3   |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                                     |       |
|---|---------------|-----------|-------------------------------------|-------|
|   | Director      | 10% Owner | Officer                             | Other |
| GOLDBERG MURRAY A<br>777 OLD SAW MILL RIVER ROAD<br>TARRYTOWN, NY 10591 |               |           | SVP<br>Administration &<br>Asst Sec |       |

## Signatures

/s/\*\*Murray A.  
Goldberg

02/26/2014

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

- (2) Represents volume-weighted average price of sales of 275 shares of Company stock on February 25, 2014 at prices ranging from \$336.88 to \$336.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2014 at each separate price.
- (3) Represents volume-weighted average price of sales of 1,962 shares of Company stock on February 25, 2014 at prices ranging from \$337.00 to \$337.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2014 at each separate price.
- (4) Represents volume-weighted average price of sales of 3,934 shares of Company stock on February 25, 2014 at prices ranging from \$338.00 to \$338.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2014 at each separate price.
- (5) Represents volume-weighted average price of sales of 1,300 shares of Company stock on February 25, 2014 at prices ranging from \$339.00 to \$339.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2014 at each separate price.
- (6) Represents volume-weighted average price of sales of 1,200 shares of Company stock on February 25, 2014 at prices ranging from \$340.15 to \$340.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2014 at each separate price.
- (7) Represents volume-weighted average price of sales of 2,100 shares of Company stock on February 25, 2014 at prices ranging from \$341.05 to \$341.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2014 at each separate price.
- (8) Represents volume-weighted average price of sales of 500 shares of Company stock on February 25, 2014 at prices ranging from \$342.00 to \$342.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2014 at each separate price.
- (9) Represents volume-weighted average price of sales of 200 shares of Company stock on February 25, 2014 at prices ranging from \$344.07 to \$344.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2014 at each separate price.
- (10) Represents volume-weighted average price of sales of 300 shares of Company stock on February 25, 2014 at prices ranging from \$346.58 to \$346.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2014 at each separate price.
- (11) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.